Medical management of coral reef aorta through optimised diuretic use and angiotensin receptor blockade

Nicodemus Edrick Oey1, Haresh Tulsidas2, Krithikaa Nadarajan3

  • 1Department of Rehabilitation Medicine, Singapore General Hospital, Singapore.

BMJ Case Reports
|June 4, 2021
PubMed

Insights

Coral reef aorta (CRA), a rare condition causing severe hypertension and kidney issues, can now be medically managed. This study presents the first case of successful non-surgical treatment using diuretics and angiotensin receptor blockers.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Vascular Surgery

Background:

  • Coral reef aorta (CRA) is a rare, severe condition involving aortic calcification and stenosis.
  • It typically affects the juxtarenal or suprarenal aorta, leading to refractory hypertension and renal dysfunction.
  • Current treatments, including surgery and endovascular stenting, carry significant risks.

Observation:

  • This report details the case of a patient diagnosed with CRA.
  • The patient presented with severe hypertension and impaired renal function.
  • Standard surgical interventions were considered high-risk.

Findings:

  • The patient was successfully managed with medical therapy, specifically diuretics and angiotensin receptor blockade.
  • This non-surgical approach avoided the high morbidity and mortality associated with CRA interventions.
  • This represents the first documented case of successful medical management for CRA.

Implications:

  • Medical management with diuretics and ARBs offers a viable, less invasive alternative for CRA patients.
  • This approach may reduce the need for high-risk surgical or endovascular procedures.
  • Further research into non-surgical CRA treatments is warranted to improve patient outcomes.

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
99
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
85
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
90
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
636
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
61
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
87